Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $21.18M rose 17.9% year over year, ahead of the +11.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +17.9% holds above the trailing-twelve-month pace of +11.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 83.25M USD
- Year-over-year change
- +18.0%
- 4-year CAGR
- +22.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 83.25M | +18.0% |
| FY2024 | 2024-12-31 | 70.58M | +64.1% |
| FY2023 | 2023-12-31 | 43M | -51.4% |
| FY2022 | 2022-12-31 | 88.43M | +139.9% |
| FY2021 | 2021-12-31 | 36.87M | — |
Operating Expenses vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 operating expenses of $86.47M is the 10th highest of the 11 companies compared; the peer median is $115.17M.
- Its year-over-year change of +11.3% is the 5th highest of 11, against a peer median of +7.0%.
- Over three fiscal years its annual growth of -2.0% compares with a peer median of +13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.73M | +36.9% | +16.5% | 166.1% | |
| LTM Mar 2026 | $149.1M | +7.6% | +38.4% | — | |
| LTM Mar 2026 | $144.1M | -14.3% | +22.2% | 2511.3% | |
| LTM Mar 2026 | $139.67M | +6.4% | -3.8% | 61.5% | |
| LTM Mar 2026 | $117.37M | -46.1% | -16.4% | 303.3% | |
| LTM Mar 2026 | $112.97M | -32.5% | -15.4% | — | |
| LTM Mar 2026 | $100.3M | +45.7% | +21.8% | 689.8% | |
| LTM Mar 2026 | $98.8M | -9.8% | +5.9% | 4900.7% | |
| LTM Mar 2026 | $95.79M | +126.8% | +68.5% | 262.5% | |
| LTM Mar 2026 | $86.47M | +11.3% | -2.0% | — | |
| LTM Mar 2026 | $52.34M | +13.8% | +10.2% | — | |
| Peer median (excluding ELDN) | $115.17M | +7.0% | +13.4% | 303.3% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.